Mineralocorticoid receptor antagonists like spironolactone are known to reduce mortality in patients following myocardial infarction (MI) with heart failure . However, the beneficial effects of regular use of spironolactone after MI remain unclear. A study has investigated the effects of spironolactone on 7,062 patients with MI from 14 different countries, where 3,537 patients were treated with spironolactone and 3,525 patients with the placebo.
The study observed 183 events, including cardiovascular death or new or worsening heart failure, in the patients receiving spironolactone compared to 220 events in the placebo group. Notably, spironolactone reduced the risk of new or worsening heart failure by 31% compared to patients receiving colchicine with a placebo. Although spironolactone did not significantly reduce the incidence of cardiovascular death or heart failure, it did reduce the…
